Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8357-8362

  Hisamuddin, Irfan M ^a   Wehbi, Mohammad A ^a   Chao, Ann ^b   Wyre, Hadley W ^a   Hylind, Linda M ^c   Giardiello, Francis M ^c   Yang, Vincent W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; FLAVIN MONOOXYGENASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; SULINDAC; THROMBOXANE B2; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAMILIAL COLON POLYPOSIS; FMO3 GENE; GENE; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ADENOMATOUS POLYPOSIS COLI; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; COHORT STUDIES; GENOTYPE; HOMOZYGOTE; HUMANS; INTESTINAL MUCOSA; OXYGENASES; PLACEBOS; POLYMORPHISM, GENETIC; PROSTAGLANDINS; SULINDAC;

EID: 11144226352     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1073     Document Type: Article

References (38)

1. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst (Bethesda) 2002;94:252-66.
3. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
4. Sandier RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
5. Keller JJ, Giardiello FM. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther 2003;2:S140-9.
6. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
7. Cruz-Correa M, Giardiello FM. Familial adenomatous polyposis. Gastrointest Endosc 2003;58:885-94.
8. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641-5.
9. Giardiello FM, Offerhaus JA, Tersmette AC, et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996;38:578-81.
10. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
11. Yang VW, Geiman DE, Hubbard WC, et al. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat 2000;60:83-96.
12. Giardiello FM, Spannhake EW, DuBois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1998;43:311-6.
13. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9.
14. Giardiello FM, Casero RA Jr, Hamilton SR, et al. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;126:425-31.
15. Duggan DE, Hooke KF, Risley EA, Shen TY, Arman CG. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 1977;201:8-13.
16. Etienne F, Resnick L, Sagher D, Brot N, Weissbach H. Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Biochem Biophys Res Commun 2003;312:1005-10.
17. Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, Hall SD. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol 2000;60:7-17.
18. Ziegler DM. Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. Trends Pharmacol Sci 1990;11:321-4.
19. Ziegler DM. Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 1993;33:179-99.
20. Lawton MP, Cashman JR, Cresteil T, et al. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 1994;308:254-7.
21. Phillips IR, Dolphin CT, Clair P, et al. The molecular biology of the flavin-containing monooxygenases of man. Chem Biol Interact 1995;96:17-32.
22. Dolphin CT, Cullingford TE, Shephard EA, Smith RL, Phillips IR. Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. Eur J Biochem 1996;235:683-9.
23. Cashman JR, Zhang J. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos 2002;30:1043-52.
24. Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR. Trimethylaminuria and a human FMO3 mutation database. Hum Mutat 2003;22:209-13.
25. Sachse C, Ruschen S, Dettling M, et al. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin Pharmacol Ther 1999;66:431-8.
26. Cashman JR, Zhang J, Leushner J, Braun A. Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab Dispos 2001;29:1629-37.
27. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
28. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-9.
29. DuBois RN. Cyclooxygenase-2 and colorectal cancer. Prog Exp Tumor Res 2003;37:124-37.
30. Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998;58:1750-3.
31. Krueger SK, Williams DE, Yueh MF, et al. Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metab Rev 2002;34:523-32.
32. Cashman JR, Akerman BR, Forrest SM, Treacy EP. Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug Metab Dispos 2000;28:169-73.
33. Cashman JR. Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 2002;3:325-39.
34. Zschocke J, Kohlmueller D, Quak E, Meissner T, Hoffmann GF, Mayatepek E. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 1999;354:834-5.
35. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet 1997;17:491-4.
36. Park CS, Kang JH, Chung WG, et al. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 2002;12:77-80.
37. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 2003;31:854-60.
38. Stornier E, Roots I, Brockmoller J. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 2000;50:553-61.